Dr. Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health.
Since joining KPCB in 2005, Beth has incubated five companies and serves on the board of directors of 3-V Biosciences, Armo Biosciences, Atara, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO.
Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc.
Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals.
Beth received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.
Advisory Roles (10)Update
- 08/28/12 -techcrunch.com
- 05/22/12 -techcrunch.com
- 05/17/12 -techcrunch.com